Processing-induced reduction in dianthrones content and toxicity of Polygonum multiflorum: Insights from ultra-high performance liquid chromatography triple quadrupole mass spectrometry analysis and toxicological assessment

Abstract

Background: Polygonum multiflorum-induced liver injury (PM-DILI) has significantly hindered its clinical application and development.

Methods: This study investigates the variation in content and toxicity of dianthrones, the toxic components of P. multiflorum, during different processing cycles. We employed the ultra-high-performance liquid chromatography triple quadrupole mass spectrometry method to quantify six dianthrones in raw P. multiflorum and formulations processed with a method called nine cycles of steaming and sunning. Additionally, toxicity assessments were conducted using human normal liver cell line L02 and zebrafish embryos.

Results: Results indicate a gradual reduction in dianthrones content with increasing processing cycles. Processed formulations exhibited significantly reduced cytotoxicity in L02 cells and hepatotoxicity in zebrafish embryos.

Conclusions: Our findings elucidate the relationship between processing cycles and P. multiflorum toxicity, providing theoretical support for its safe use.

Keywords

dianthrones / hepatotoxicity / Polygonum multiflorum Thunb. / ultra-high performance liquid chromatography triple quadrupole mass spectrometry (UHPLC-QQQ-MS/MS) / zebrafish embryos

References

[1] Kullak-Ublick GA, Andrade RJ, Merz M, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 2017; 66(6): 1154-1164.

[2] Babai S, Auclert L, Le-Louët H. Safety data and withdrawal of hepatotoxic drugs. Therapeie. 2021; 76(6): 715-723.

[3] Katarey D, Verma S. Drug-induced liver injury. Clin Med. 2016; 16(Suppl 6): S104-S109.

[4] Weaver RJ, Blomme EA, Chadwick AE, et al. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. Nat Rev Drug Discov. 2020; 19(2): 131-148.

[5] Liu A, Walter M, Wright P, et al. Prediction and mechanistic analysis of drug-induced liver injury (DILI) based on chemical structure. Biol Direct. 2021; 16(1): 6.

[6] Li T, Tong W, Roberts R, Liu Z, Thakkar S. DeepDILI: deep learning-powered drug-induced liver injury prediction using model-level representation. Chem Res Toxicol. 2021; 34(2): 550-565.

[7] Cox CR, Lynch S, Goldring C, Sharma P. Current perspective: 3D spheroid models utilizing human-based cells for investigating metabolism-dependent drug-induced liver injury. Front Med Technol. 2021; 2: 611913.

[8] Shi Q, Arefin A, Ren L, et al. Co-culture of human primary hepatocytes and nonparenchymal liver cells in the emulate® liver-Chip for the study of drug-induced liver injury. Curr Protoc. 2022; 2(7): e478.

[9] Kuna L, Bozic I, Kizivat T, et al. Models of drug induced liver injury (DILI) - current issues and future perspectives. Curr Drug Metab. 2018; 19(10): 830-838.

[10] Miyawaki I. Application of zebrafish to safety evaluation in drug discovery. J Toxicol Pathol. 2020; 33(4): 197-210.

[11] Foulkes MJ, Henry KM, Rougeot J, et al. Expression and regulation of drug transporters in vertebrate neutrophils. Sci Rep. 2017; 7(1): 4967.

[12] Saad M, Cavanaugh K, Verbueken E, et al. Xenobiotic metabolism in the zebrafish: a review of the spatiotemporal distribution, modulation and activity of cytochrome P450 families 1 to 3. J Toxicol Sci. 2016; 41(1): 1-11.

[13] Katoch S, Patial V. Zebrafish: An emerging model system to study liver diseases and related drug discovery. J Appl Toxicol. 2021; 41(1): 33-51.

[14] Yu Q, Huo J, Zhang Y, et al. Tamoxifen-induced hepatotoxicity via lipid accumulation and inflammation in zebrafish. Chemosphere. 2020; 239: 124705.

[15] Zhang Y, Han L, He Q, et al. A rapid assessment for predicting drug-induced hepatotoxicity using zebrafish. J Pharmacol Toxicol Methods. 2017; 84: 102-110.

[16] Li HY, Yang JB, Li WF, et al. In vivo hepatotoxicity screening of different extracts, components, and constituents of Polygoni Multiflori Thunb. In zebrafish (Danio rerio) larvae. Biomed Pharmacother. 2020; 131: 110524.

[17] Lin L, Ni B, Lin H, et al. Traditional usages, botany, phytochemistry, pharmacology and toxicology of Polygonum multiflorum Thunb.: a review. J Ethnopharmacol. 2015; 159: 158-183.

[18] Ho TT, Murthy HN, Dalawai D, Bhat MA, Paek KY, Park SY. Attributes of Polygonum multiflorum to transfigure red biotechnology. Appl Microbiol Biotechnol. 2019; 103(8): 3317-3326.

[19] Bounda GA, Feng Y. Review of clinical studies of Polygonum multiflorum Thunb. And its isolated bioactive compounds. Pharmacognosy. Research. 2015; 7(3): 225-236.

[20] Alkhatib A, Seijo M, Larumbe E, Naclerio F. Acute effectiveness of a "fat-loss" product on substrate utilization, perception of hunger, mood state and rate of perceived exertion at rest and during exercise. J Int Soc Sports Nutr. 2015; 12: 44.

[21] Oerter Klein K, Janfaza M, Wong JA, et al. Estrogen bioactivity in fo-ti and other herbs used for their estrogen-like effects as determined by a recombinant cell bioassay. J Clin Endocrinol Metab. 2003; 88(9): 4077-4079.

[22] Zhu Y-P. Chinese Materia Medica: Chemistry. CRC Press; 1998.

[23] Ying Z, Zhongjia D. The processing history research of radix Polygoni Multiflori. Chin Med Herald. 2010; 7: 9-10.

[24] Wu X, Chen X, Huang Q, Fang D, Li G, Zhang G. Toxicity of raw and processed roots of Polygonum multiflorum. Fitoterapia. 2012; 83(3): 469-475.

[25] Liang Z, Chen H, Yu Z, Zhao Z. Comparison of raw and processed radix Polygoni Multiflori (Heshouwu) by high performance liquid chromatography and mass spectrometry. Chin Med. 2010; 5: 29.

[26] Yu XA, Ge AH, Zhang L, et al. Influence of different processing times on the quality of Polygoni multiflora radix by metabolomics based on ultra high performance liquid chromatography with quadrupole time-of-flight mass spectrometry. J Sep Sci. 2017; 40(9): 1928-1941.

[27] Guangqiang Y. The processing history of Polygonum multiflorum. J North Phar. 2014; 3: 63-64.

[28] Jianhai N. A severe liver damage case induced by Shou Wu Pian though Oral administration. Chin J New Drug Clin Rem. 1996; 06: 63.

[29] Wang S, Li X, Guo H, et al. Emodin alleviates hepatic steatosis by inhibiting sterol regulatory element binding protein 1 activity by way of the calcium/calmodulin-dependent kinase kinase-AMP-activated protein kinase-mechanistic target of rapamycin-p70 ribosomal S6 kinase signaling pathway. Hepatol Res. 2017; 47(7): 683-701.

[30] Wang X, Niu C, Zhang X, Dong M. Emodin suppresses activation of hepatic stellate cells through p38 mitogen-activated protein kinase and Smad signaling pathways in vitro. Phytother Res. 2018; 32(12): 2436-2446.

[31] Yu W, Zhang X, Wu H, et al. HO-1 is essential for Tetrahydroxystilbene glucoside mediated mitochondrial biogenesis and anti-inflammation process in LPS-treated RAW264.7 macrophages. Oxidative Med Cell Longev. 2017; 2017: 1818575.

[32] Liu Y, Wang Q, Yang J, et al. Polygonum multiflorum Thunb.: a review on chemical analysis, processing mechanism, quality evaluation, and hepatotoxicity. Front Pharmacol. 2018; 9: 364.

[33] Teka T, Wang L, Gao J, et al. Polygonum multiflorum: recent updates on newly isolated compounds, potential hepatotoxic compounds and their mechanisms. J Ethnopharmacol. 2021; 271: 113864.

[34] Liu Y, Wang W, Sun M, et al. Polygonum multiflorum-induced liver injury: clinical characteristics, risk factors, material basis, action mechanism and current challenges. Front Pharmacol. 2019; 10: 1467.

[35] Rao T, Liu YT, Zeng XC, Li CP, Ou-Yang DS. The hepatotoxicity of Polygonum multiflorum: the emerging role of the immune-mediated liver injury. Acta Pharmacol Sin. 2021; 42(1): 27-35.

[36] Yang JB, Li WF, Liu Y, et al. Acute toxicity screening of different extractions, components and constituents of Polygonum multiflorum Thunb. On zebrafish (Danio rerio) embryos in vivo. Biomed Pharmacother. 2018; 99: 205-213.

[37] Yang JB, Song YF, Liu Y, et al. UHPLC-QQQ-MS/MS assay for the quantification of dianthrones as potential toxic markers of Polygonum multiflorum Thunb: applications for the standardization of traditional Chinese medicines (TCMs) with endogenous toxicity. Chin Med. 2021; 16(1): 51.

[38] Wang Q, Wen H, Ma S, Zhang Y. Polygonum multiflorum Thunb. Induces hepatotoxicity in SD rats and hepatocyte spheroids by disrupting the metabolism of bilirubin and bile acid. J Ethnopharmacol. 2022; 296: 115461.

[39] Hu X, Du T, Dai S, et al. Identification of intrinsic hepatotoxic compounds in Polygonum multiflorum Thunb. Using machine-learning methods. J Ethnopharmacol. 2022; 298: 115620.

[40] Gao H, Yang J, Wang X, et al. Exploratory quality control study for Polygonum multiflorum Thunb. Using Dinuclear anthraquinones with potential hepatotoxicity. Molecules. 2022; 27(19): 6760.

RIGHTS & PERMISSIONS

2024 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.